Cariprazine approval provides another option in treating mental illness
from By Dr. Abimbola Farinde
The recent FDA approval of the atypical or second-generation antipsychotic cariprazine (Vraylar) gives prescribers another option on the list of atypical antipsychotics that are used to treat acute manic or mixed episodes associated with bipolar I disorder and schizophrenia in adults. In certain cases, it can take years before an individual is correctly and formally diagnosed with either one of these conditions.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063